FDA Issues Safety Warning on Lunesta

In mid-May, the FDA released a warning that eszopiclone (Lunesta) can cause next-day impairment when taken at the recommended target dose of 3 mg/day. As a result, the FDA has lowered the recommended starting dose to 1 mg/day.

Current Subscribers

Purchase a subscription

To view the full content, you need to purchase a subscription.